Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant

Immune checkpoint inhibitors (ICIs) and brentuximab vedotin (BV) are novel agents for classic Hodgkin lymphoma, including relapse after autologous stem cell transplant (ASCT). However, their impact on survival post-ASCT relapse, in comparison with conventional therapy, is less known due to the lack...

Full description

Bibliographic Details
Main Authors: Aung M. Tun, Yucai Wang, Aasiya Matin, David J. Inwards, Thomas M. Habermann, Ivana Micallef, Patrick B. Johnston, Luis Porrata, Jonas Paludo, Jose Villasboas Bisneto, Allison Rosenthal, Han W. Tun, James R. Cerhan, Thomas E. Witzig, Grzegorz S. Nowakowski, Stephen M. Ansell
Format: Article
Language:English
Published: Wiley 2023-04-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000869

Internet

http://journals.lww.com/10.1097/HS9.0000000000000869

Similar Items